H. Joachim J. Deeg

H. Joachim J. Deeg's AcademicInfluence.com Rankings

H. Joachim J. Deeg

Biology

#5484

World Rank

#7976

Historical Rank

Molecular Biology

#491

World Rank

#502

Historical Rank

Biochemistry

#654

World Rank

#752

Historical Rank

biology Degrees

Download Badge

Biology

H. Joachim J. Deeg's Degrees

PhD Biochemistry University of California, Berkeley
Bachelors Chemistry University of California, Berkeley

Why Is H. Joachim J. Deeg Influential?

(Suggest an Edit or Addition)

(See a Problem?)

H. Joachim J. Deeg's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Massively parallel digital transcriptional profiling of single cells (2016) (3559)
Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. (1986) (1400)
Solid cancers after bone marrow transplantation. (1997) (767)
Pregnancies following high-dose cyclophosphamide with or without high-dose busulfan or total-body irradiation and bone marrow transplantation. (1996) (655)
Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. (1999) (632)
A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. (2004) (620)
Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. (1997) (618)
Marrow transplantation for the treatment of chronic myelogenous leukemia. (1986) (561)
Hematopoietic stem cell compartment: acute and late effects of radiation therapy and chemotherapy. (1995) (435)
SRSF2 Mutations Contribute to Myelodysplasia by Mutant-Specific Effects on Exon Recognition. (2015) (434)
Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: long-term follow-up of a controlled trial. (1989) (428)
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes. (2017) (414)
Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. (2008) (401)
Acute graft-versus-host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate. (1992) (399)
Solid cancers after allogeneic hematopoietic cell transplantation. (2009) (395)
Secondary cancers after bone marrow transplantation for leukemia or aplastic anemia. (1989) (394)
How I treat refractory acute GVHD. (2007) (390)
Malignancies after marrow transplantation for aplastic anemia and fanconi anemia: a joint Seattle and Paris analysis of results in 700 patients. (1996) (375)
Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. (1994) (365)
Marrow transplantation for severe aplastic anemia: methotrexate alone compared with a combination of methotrexate and cyclosporine for prevention of acute graft-versus-host disease. (1986) (350)
Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. (1997) (350)
Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. (2009) (347)
Nephrotoxicity of cyclosporin A after allogeneic marrow transplantation: glomerular thromboses and tubular injury. (1981) (343)
Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hematopoietic stem cell transplantation. (2003) (326)
New malignant diseases after allogeneic marrow transplantation for childhood acute leukemia. (2000) (314)
Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemia. (1994) (311)
Effects of in vitro depletion of T cells in HLA-identical allogeneic marrow grafts (1985) (309)
A disease risk index for patients undergoing allogeneic stem cell transplantation. (2012) (305)
International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). (2006) (302)
Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT). (2007) (297)
Predictive factors in chronic graft-versus-host disease in patients with aplastic anemia treated by marrow transplantation from HLA-identical siblings. (1983) (295)
Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European Group for Blood and Marrow Transplantation, Société Française de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center Collaborative Study. (1999) (287)
Alternating-day cyclosporine and prednisone for treatment of high-risk chronic graft-v-host disease. (1988) (279)
NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes. (2011) (277)
Effects of in vitro depletion of T cells in HLA-identical allogeneic marrow grafts. (1985) (275)
Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. (2002) (269)
Treatment of malignant lymphoma in 100 patients with chemotherapy, total body irradiation, and marrow transplantation. (1987) (257)
Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone. (2002) (253)
HLA-Identical Sibling Bone Marrow Transplantation in Younger Patients with Chronic Lymphocytic Leukemia (1996) (247)
Malignancies after hematopoietic stem cell transplantation: many questions, some answers. (1998) (243)
Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. (2017) (236)
Growth and development following marrow transplantation for leukemia. (1986) (229)
Marrow transplantation in thirty "untransfused" patients with severe aplastic anemia. (1980) (229)
Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis. (2013) (226)
Unrelated donor marrow transplantation for myelodysplastic syndromes: outcome analysis in 510 transplants facilitated by the National Marrow Donor Program. (2002) (222)
Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease. (2019) (204)
Graft failure in patients receiving T cell-depleted HLA-identical allogeneic marrow transplants. (1988) (201)
Pomalidomide is active in the treatment of anemia associated with myelofibrosis. (2009) (198)
Cataracts after total body irradiation and marrow transplantation: a sparing effect of dose fractionation. (1984) (197)
Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55 to 66 years of age. (2000) (195)
Long-term outcome after marrow transplantation for severe aplastic anemia. (1998) (186)
Methotrexate, cyclosporine, or both to prevent graft-versus-host disease after HLA-identical sibling bone marrow transplants for early leukemia? (1993) (186)
Cyclosporine as prophylaxis for graft-versus-host disease: a randomized study in patients undergoing marrow transplantation for acute nonlymphoblastic leukemia. (1985) (186)
Marrow harvesting from normal donors. (1984) (182)
SIROLIMUS (RAPAMYCIN) FOR THE TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE1 (2001) (182)
Treatment of acute graft-versus-host disease with humanized anti-Tac: an antibody that binds to the interleukin-2 receptor. (1994) (177)
Bone marrow transplantation or chemotherapy after remission induction for adults with acute nonlymphoblastic leukemia. A prospective comparison. (1984) (169)
Optimization of conditioning for marrow transplantation from unrelated donors for patients with aplastic anemia after failure of immunosuppressive therapy. (2006) (160)
A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease. (2002) (158)
Hyperacute graft-v-host disease in patients not given immunosuppression after allogeneic marrow transplantation. (1986) (155)
BONE MARROW TRANSPLANTATION: A REVIEW OF DELAYED COMPLICATIONS (1984) (154)
Late effects on gonadal function of cyclophosphamide, total-body irradiation, and marrow transplantation. (1983) (154)
Stable mixed hematopoietic chimerism in dogs given donor antigen, CTLA4Ig, and 100 cGy total body irradiation before and pharmacologic immunosuppression after marrow transplant. (1999) (152)
Marrow transplantation for aplastic anemia. (1974) (152)
Cyclophosphamide and antithymocyte globulin to condition patients with aplastic anemia for allogeneic marrow transplantations: the experience in four centers. (2001) (150)
Stable mixed hematopoietic chimerism in dog leukocyte antigen-identical littermate dogs given lymph node irradiation before and pharmacologic immunosuppression after marrow transplantation. (1999) (149)
Synergism between mycophenolate mofetil and cyclosporine in preventing graft-versus-host disease among lethally irradiated dogs given DLA-nonidentical unrelated marrow grafts. (1998) (149)
Bone marrow transplantation in patients aged 45 years and older. (1986) (148)
FK506 in combination with methotrexate for the prevention of graft-versus-host disease after marrow transplantation from matched unrelated donors. (1996) (146)
ACUTE RENAL TOXICITY WITH COMBINED USE OF AMPHOTERICIN B AND CYCLOSPORINE AFTER MARROW TRANSPLANTATION (1983) (146)
Graft-versus-host disease: pathophysiological and clinical aspects. (1984) (145)
Impact of patient weight on non-relapse mortality after marrow transplantation. (1995) (142)
Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS. (2012) (142)
Marrow transplantation for acute nonlymphoblastic leukemia in first remission: toxicity and long-term follow-up of patients conditioned with single dose or fractionated total body irradiation. (1986) (140)
Effect of stem cell source on outcomes after unrelated donor transplantation in severe aplastic anemia. (2011) (137)
Allogeneic hematopoietic stem cell transplantation for myelofibrosis. (2003) (136)
Dysregulation of IL-32 in myelodysplastic syndrome and chronic myelomonocytic leukemia modulates apoptosis and impairs NK function (2008) (133)
Negative Regulators of Hemopoiesis and Stroma Function in Patients with Myelodysplastic Syndrome (2000) (131)
A controlled trial of long-term administration of intravenous immunoglobulin to prevent late infection and chronic graft-vs.-host disease after marrow transplantation: clinical outcome and effect on subsequent immune recovery. (1996) (129)
Late complications after marrow transplantation. (1984) (125)
Marrow transplants from unrelated donors for patients with aplastic anemia: minimum effective dose of total body irradiation. (2001) (124)
Serum cyclosporine concentration and risk of acute graft-versus-host disease after allogeneic marrow transplantation. (1988) (123)
Ablative allogeneic hematopoietic cell transplantation in adults 60 years of age and older. (2005) (123)
Red blood cell transfusion dependence and outcome after allogeneic peripheral blood stem cell transplantation in patients with de novo myelodysplastic syndrome (MDS). (2008) (122)
Expression of tumor necrosis factor-related apoptosis-inducing ligand, Apo2L, and its receptors in myelodysplastic syndrome: effects on in vitro hemopoiesis. (2001) (120)
Thalidomide for treatment of patients with chronic graft-versus-host disease. (2000) (118)
CYCLOSPORIN A AND METHOTREXATE IN CANINE MARROW TRANSPLANTATION: ENGRAFTMENT, GRAFT‐VERSUS-HOST DISEASE, AND INDUCTION OF TOLERANCE (1982) (110)
Cyclosporine or cyclosporine plus methylprednisolone for prophylaxis of graft-versus-host disease: a prospective, randomized trial. (1997) (108)
Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-v-host disease: prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation. (1988) (107)
Apoptosis and antiapoptotic mechanisms in the progression of myelodysplastic syndrome. (2007) (107)
Marrow transplantation for chronic myelocytic leukemia: a controlled trial of cyclosporine versus methotrexate for prophylaxis of graft-versus-host disease. (1985) (106)
Outcomes of allogeneic hematopoietic cell transplantation in patients with dyskeratosis congenita. (2013) (106)
Soluble TNF receptor fusion protein (etanercept) for the treatment of myelodysplastic syndrome: A pilot study (2002) (105)
Effect of mixed chimerism on graft-versus-host disease, disease recurrence and survival after HLA-identical marrow transplantation for aplastic anemia or chronic myelogenous leukemia. (1996) (103)
Graft‐versus‐host disease prevention by methotrexate combined with cyclosporin compared to methotrexate alone in patients given marrow grafts for severe aplastic anaemia: long‐term follow‐up of a controlled trial (1989) (102)
Treatment of steroid-refractory acute graft-versus-host disease with anti-CD147 monoclonal antibody ABX-CBL. (2001) (99)
Marrow transplantation with or without donor buffy coat cells for 65 transfused aplastic anemia patients. (1982) (99)
Incidence, risk factors, and mortality from pneumonia developing late after hematopoietic stem cell transplantation (2003) (98)
NF-kappaB and FLIP in arsenic trioxide (ATO)-induced apoptosis in myelodysplastic syndromes (MDSs). (2005) (97)
Allogeneic marrow transplantation in the treatment of preleukemia. (1984) (95)
Decreased incidence of marrow graft rejection in patients with severe aplastic anemia: changing impact of risk factors. (1986) (93)
Who is fit for allogeneic transplantation? (2010) (92)
Marrow transplantation for patients in accelerated phase of chronic myeloid leukemia. (1994) (91)
Marrow transplantation from unrelated donors for patients with severe aplastic anemia who have failed immunosuppressive therapy. (1999) (90)
Marrow transplantation for severe aplastic anemia. Long-term outcome in fifty "untransfused" patients. (1986) (89)
Effects of recombinant canine stem cell factor, a c-kit ligand, and recombinant granulocyte colony-stimulating factor on hematopoietic recovery after otherwise lethal total body irradiation. (1993) (89)
Myelodysplastic syndromes clinical practice guidelines in oncology. (2006) (87)
The clinical spectrum of acute graft-versus-host disease. (2006) (87)
DLA-identical bone marrow grafts after low-dose total body irradiation: effects of high-dose corticosteroids and cyclosporine on engraftment. (1995) (86)
Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen. (2006) (85)
Age‐dependent cyclosporine: Pharmacokinetics in marrow transplant recipients (1986) (85)
Adverse effect of severe marrow fibrosis on hematologic recovery after chemoradiotherapy and allogeneic bone marrow transplantation. (1986) (83)
Increased incidence of Hodgkin's disease after allogeneic bone marrow transplantation. (1999) (83)
Treatment of human acute graft-versus-host disease with antithymocyte globulin and cyclosporine with or without methylprednisolone. (1985) (82)
Secondary malignancies after marrow transplantation. (1984) (82)
A phase 2/3 multicenter randomized clinical trial of ABX-CBL versus ATG as secondary therapy for steroid-resistant acute graft-versus-host disease. (2007) (82)
Hematopoietic stem-cell transplantation for treatment-related leukemia or myelodysplasia. (2001) (82)
Marrow transplantation for thalassemia. (1985) (78)
FAILURE OF ALLOGENEIC CANINE MARROW GRAFTS AFTER TOTAL‐BODY IRRADIATION: ALLOGENEIC “RESISTANCE” VERSUS TRANSFUSION‐INDUCED SENSITIZATION (1986) (78)
Phenotyping of canine lymphoma with monoclonal antibodies directed at cell surface antigens: Classification, morphology, clinical presentation and response to chemotherapy (1984) (77)
Treatment of acute graft-versus-host disease after allogeneic marrow transplantation. Randomized study comparing corticosteroids and cyclosporine. (1985) (77)
Phase 2 study of lenalidomide in transfusion-dependent , low-risk , and intermediate-1 – risk myelodysplastic syndromes with karyotypes other than deletion 5 q (2007) (76)
The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of myelodysplastic syndromes: an evidence-based review. (2009) (76)
Allogeneic marrow transplantation for aplastic anaemia associated with dyskeratosis congenita (1996) (76)
High-dose fractionated total-body irradiation, etoposide, and cyclophosphamide followed by autologous stem-cell support in patients with malignant lymphoma. (1994) (75)
Cyclosporine v methotrexate for graft-v-host disease prevention in patients given marrow grafts for leukemia: long-term follow-up of three controlled trials. (1988) (75)
Phase I Dose-Escalation Trial of SB1518, a Novel JAK2/FLT3 Inhibitor, in Acute and Chronic Myeloid Diseases, Including Primary or Post-Essential Thrombocythemia/ Polycythemia Vera Myelofibrosis. (2009) (75)
Retrovirus-mediated gene transduction into canine peripheral blood repopulating cells. (1994) (74)
Late effects among pediatric patients followed for nearly 4 decades after transplantation for severe aplastic anemia. (2011) (72)
Inhibition of IL-32 activation by α-1 antitrypsin suppresses alloreactivity and increases survival in an allogeneic murine marrow transplantation model. (2011) (72)
Allogeneic marrow transplantation in the treatment of MOPP-resistant Hodgkin's disease. (1985) (72)
Long-term follow-up of allogeneic marrow transplants in patients with aplastic anemia conditioned by cyclophosphamide combined with antithymocyte globulin. (1997) (72)
Results of a Phase III Randomized, Multi-Center Study of Allogeneic Stem Cell Transplantation after High Versus Reduced Intensity Conditioning in Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML): Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0901 (2015) (71)
Myeloablation and autologous peripheral blood stem cell rescue results in hematologic and clinical responses in patients with myeloid metaplasia with myelofibrosis. (2001) (70)
Marrow transplant experience in children with acute lymphoblastic leukemia: an analysis of factors associated with survival, relapse, and graft-versus-host disease. (1985) (69)
Incidence of hypertension after marrow transplantation among 112 patients randomized to either cyclosporine or methotrexate as graft‐versus‐host disease prophylaxis (1985) (69)
Splenectomy and hemopoietic stem cell transplantation for myelofibrosis. (2001) (69)
T-cell intestinal lymphoma associated with celiac sprue. (1986) (68)
HIGH CYCLOSPORIN LEVELS AFTER BONE MARROW TRANSPLANTATION ASSOCIATED WITH HYPERTRIGLYCERIDAEMIA (1986) (68)
Administration of cyclosporine for 24 months compared with 6 months for prevention of chronic graft-versus-host disease: a prospective randomized clinical trial. (2001) (67)
Therapy with mycophenolate mofetil for refractory acute and chronic graft-versus-host disease (2009) (66)
RECOVERY OF IN VIVO CELLULAR IMMUNITY AFTER HUMAN MARROW GRAFTING: Influence of Time Postgrafting and Acute Graft‐Versus‐Host Disease (1984) (66)
Immunological recovery in 48 patients following syngeneic marrow transplantation or hematological malignancy. (1982) (66)
Allogeneic bone marrow transplantation in children with myelodysplastic syndrome or juvenile myelomonocytic leukemia: the Seattle experience (2004) (65)
Consensus Opinion on Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis. (2016) (63)
Changing trends in marrow transplantation for aplastic anemia. (1992) (63)
Total body irradiation dose and risk of subsequent neoplasms following allogeneic hematopoietic cell transplantation. (2019) (63)
Secondary malignancies after marrow transplantation for leukemia or aplastic anemia. (1994) (63)
Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome after conditioning with busulfan and fractionated total body irradiation is associated with low relapse rate but considerable nonrelapse mortality. (2002) (63)
Correlation of hypomagnesemia with the onset of cyclosporine-associated hypertension in marrow transplant patients. (1986) (62)
Cyclophosphamide conditioning in patients with severe aplastic anaemia given unrelated marrow transplantation: a phase 1-2 dose de-escalation study. (2015) (62)
Prevention of platelet alloimmunization in dogs with systemic cyclosporine and by UV-irradiation or cyclosporine-loading of donor platelets (1987) (62)
Hematologic responses of patients with MDS to antithymocyte globulin plus etanercept correlate with improved flow scores of marrow cells. (2004) (62)
Long-term survival and reversal of iron overload after marrow transplantation in dogs with congenital hemolytic anemia. (1981) (61)
Expression of FLIPLong and FLIPShort in bone marrow mononuclear and CD34+ cells in patients with myelodysplastic syndrome: correlation with apoptosis (2003) (61)
Marrow toxicity of fractionated vs. single dose total body irradiation is identical in a canine model. (1993) (61)
Reproducibility in retrospective grading of acute graft-versus-host disease after allogeneic marrow transplantation (1998) (61)
Conditioning for allogeneic marrow transplantation in patients with lymphohematopoietic malignancies without the use of total body irradiation. (1992) (61)
Abrogation of resistance to and enhancement of DLA-nonidentical unrelated marrow grafts in lethally irradiated dogs by thoracic duct lymphocytes. (1979) (59)
Bone marrow transplantation for severe aplastic anemia from genotypically HLA-nonidentical relatives. An update of the Seattle experience. (1996) (59)
Acute and delayed toxicities of total body irradiation. Seattle Marrow Transplant Team. (1983) (58)
Results of a Clinical Trial of H3B-8800, a Splicing Modulator, in Patients with Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML) (2019) (58)
Allogeneic hematopoietic cell transplantation for fanconi anemia in patients with pretransplantation cytogenetic abnormalities, myelodysplastic syndrome, or acute leukemia. (2013) (58)
Cyclosporin A, a powerful immunosuppressant in vivo and in vitro in the dog, fails to induce tolerance. (1980) (57)
NOD/SCID mice transplanted with marrow from patients with myelodysplastic syndrome (MDS) show long-term propagation of normal but not clonal human precursors. (2003) (57)
Rejection of marrow from DLA-identical canine littermates given transfusions before grafting: antigens involved are expressed on leukocytes and skin epithelial cells but not on platelets and red blood cells. (1979) (56)
Marrow transplantation following escalating doses of fractionated total body irradiation and cyclophosphamide--a phase I trial. (1992) (56)
Clinical outcome after conversion to FK 506 (tacrolimus) therapy for acute graft-versus-host disease resistant to cyclosporine or for cyclosporine-associated toxicities (2000) (55)
Epigenetically Aberrant Stroma in MDS Propagates Disease via Wnt/β-Catenin Activation. (2017) (55)
FK‐506 AND METHOTREXATE PREVENT GRAFT‐VERSUS-HOST DISEASE IN DOGS GIVEN 9.2 Gy TOTAL BODY IRRADIATION AND MARROW GRAFTS FROM UNRELATED DOG LEUKOCYTE ANTIGEN‐NONIDENTICAL DONORS (1993) (55)
Evaluation of a CD5-specific immunotoxin for treatment of acute graft- versus-host disease after allogeneic marrow transplantation (1996) (55)
Induction of hepatic veno-occlusive disease in dogs. (1987) (54)
Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies (2016) (54)
Prevention of platelet alloimmunization in dogs with systemic cyclosporine and by UV-irradiation or cyclosporine-loading of donor platelets. (1987) (54)
Differentiation of canine bone marrow cells with hemopoietic characteristics from an adherent stromal cell precursor. (1995) (53)
Abnormalities of pulmonary function tests after marrow transplantation predict nonrelapse mortality. (1995) (53)
Ultraviolet B-induced DNA fragmentation (apoptosis) in activated T-lymphocytes and Jurkat cells is augmented by inhibition of RNA and protein synthesis. (1992) (53)
Marrow transplantation for Fanconi anemia with or without leukemic transformation: an update of the Seattle experience. (1992) (53)
Tumour necrosis factor‐induced gene expression in human marrow stroma: clues to the pathophysiology of MDS? (2008) (53)
JOINT REPORT OF THE THIRD INTERNATIONAL WORKSHOP ON CANINE IMMUNOGENETICS: II. ANALYSIS OF THE SEROLOGICAL TYPING OF CELLS (1987) (53)
COMBINED IMMUNOSUPPRESSION WITH CYCLOSPORINE AND METHOTREXATE IN DOGS GIVEN BONE MARROW GRAFTS FROM DLA‐HAPLOIDENTICAL LITTERMATES (1984) (52)
Allogeneic transplants of canine peripheral blood stem cells mobilized by recombinant canine hematopoietic growth factors (1996) (52)
Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms (2021) (52)
Marrow transplantation for Fanconi anaemia: conditioning with reduced doses of cyclophosphamide without radiation (1996) (52)
Single dose or fractionated total body irradiation and autologous marrow transplantation in dogs: effects of exposure rate, fraction size, and fractionation interval on acute and delayed toxicity. (1988) (52)
Engraftment of distinct clonal MDS-derived hematopoietic precursors in NOD/SCID-beta2-microglobulin-deficient mice after intramedullary transplantation of hematopoietic and stromal cells. (2004) (52)
Morphologic and phenotypic analysis of canine natural killer cells: evidence for T-cell lineage. (1985) (51)
Hematopoietic cell transplant for acute myeloid leukemia and myelodysplastic syndrome: conditioning regimen intensity. (2018) (51)
α-1-Antitrypsin (AAT)-modified donor cells suppress GVHD but enhance the GVL effect: a role for mitochondrial bioenergetics. (2014) (51)
The canine major histocompatibility complex. Population study of DLA-D alleles using a panel of homozygous typing cells. (2008) (51)
Prolonged disease-free survival in dogs with lymphoma after total-body irradiation and autologous marrow transplantation consolidation of combination-chemotherapy-induced remissions. (1979) (50)
Evaluation of a CD5-specific immunotoxin for treatment of acute graft-versus-host disease after allogeneic marrow transplantation. (1996) (49)
Prevention of transfusion-induced graft-versus-host disease in dogs by ultraviolet irradiation. (1989) (48)
Fas (CD95) receptor and Fas-ligand expression in bone marrow cells from patients with myelodysplastic syndrome. (1996) (48)
Murine monoclonal anti-T cell antibodies for treatment of steroid-resistant acute graft-versus-host disease. (1984) (48)
Fludarabine-based conditioning for marrow transplantation from unrelated donors in severe aplastic anemia: early results of a cyclophosphamide dose deescalation study show life-threatening adverse events at predefined cyclophosphamide dose levels. (2012) (47)
New somatic mutation in the PIG-A gene emerges at relapse of paroxysmal nocturnal hemoglobinuria. (1998) (47)
Joint report of the Third International Workshop on Canine Immunogenetics. I. Analysis of homozygous typing cells. (1986) (47)
Multicenter Validation Study of a Transplantation-Specific Cytogenetics Grouping Scheme for Patients with Myelodysplastic Syndromes (2009) (47)
Pharmacokinetic Exposure Equivalence and Preliminary Efficacy and Safety from a Randomized Cross over Phase 3 Study (ASCERTAIN study) of an Oral Hypomethylating Agent ASTX727 (cedazuridine/decitabine) Compared to IV Decitabine (2019) (46)
Ultraviolet irradiation of blood prevents transfusion-induced sensitization and marrow graft rejection in dogs (1986) (46)
Optimization of allogeneic transplant conditioning: not the time for dogma (2006) (46)
Cyclophosphamide plus ATG conditioning is insufficient for sustained hematopoietic reconstitution in patients with severe aplastic anemia transplanted with marrow from HLA-A, B, DRB matched unrelated donors. (1994) (46)
HLA-DR-triggered inhibition of hemopoiesis involves Fas/Fas ligand interactions and is prevented by c-kit ligand. (1997) (45)
Long-term survival after marrow transplantation for paroxysmal nocturnal hemoglobinuria with aplastic anemia. (1984) (45)
Ultraviolet B light inactivates bone marrow T lymphocytes but spares hematopoietic precursor cells. (1989) (45)
The helix-loop-helix transcription factor TWIST is dysregulated in myelodysplastic syndromes. (2010) (45)
Fanconi's anemia treated by allogeneic marrow transplantation. (1983) (45)
Hematopoietic Cell Transplantation for Myelofibrosis: the Dynamic International Prognostic Scoring System Plus Risk Predicts Post-Transplant Outcomes. (2018) (45)
Thrombocytopenia in dogs induced by granulocyte-macrophage colony-stimulating factor: increased destruction of circulating platelets. (1995) (44)
Prolonged responses in patients with MDS and CMML treated with azacitidine and etanercept (2010) (44)
Long-term follow-up of a randomized trial of graft-versus-host disease prevention by methotrexate/cyclosporine versus methotrexate alone in patients given marrow grafts for severe aplastic anemia [letter] (1994) (44)
Results of donor lymphocyte infusions for relapsed myelodysplastic syndrome after hematopoietic cell transplantation (2007) (44)
Fractionated versus single-dose total body irradiation at low and high dose rates to condition canine littermates for DLA-identical marrow grafts. (1994) (43)
Long‐term survival and cure after marrow transplantation for congenital hypoplastic anaemia (Diamond‐Blackfan syndrome) (1993) (43)
Simultaneous Demonstration of Clonal Chromosome Abnormalities and Apoptosis in Individual Marrow Cells in Myelodysplastic Syndrome (2004) (42)
Cure of malignant lymphoma in dogs with peripheral blood stem cell transplantation. (1986) (42)
Contact- and growth factor-dependent survival in a canine marrow-derived stromal cell line. (1995) (42)
Treatment of aplastic anemia with antithymocyte globulin, high-dose corticosteroids, and androgens. (1987) (42)
Long-term follow-up of a controlled trial comparing a combination of methotrexate plus cyclosporine with cyclosporine alone for prophylaxis of graft-versus-host disease in patients administered HLA-identical marrow grafts for leukemia [letter] (1992) (41)
Pharmacogenetics of Intravenous and Oral Busulfan in Hematopoietic Cell Transplant Recipients (2011) (41)
ULTRAVIOLET IRRADIATION OF CANINE DENDRITIC CELLS PREVENTS MITOGEN‐INDUCED CLUSTER FORMATION AND LYMPHOCYTE PROLIFERATION (1986) (41)
Low‐dose cyclophosphamide conditioning for haematopoietic cell transplantation from HLA‐matched related donors in patients with Fanconi anaemia (2005) (40)
Intravenous busulphan for conditioning before autologous or allogeneic human blood stem cell transplantation (2001) (40)
Functional dendritic cells are required for transfusion-induced sensitization in canine marrow graft recipients (1988) (40)
Increased incidence of malignant tumors in dogs after total body irradiation and marrow transplantation. (1983) (39)
Effect of graft-versus-host disease prophylaxis on relapse in patients transplanted for acute myeloid leukemia. (1994) (39)
Gamma-irradiation of pretransplant blood transfusions from unrelated donors prevents sensitization to minor histocompatibility antigens on dog leukocyte antigen-identical canine marrow grafts. (1994) (39)
Transcriptional regulation of miR-10a/b by TWIST-1 in myelodysplastic syndromes (2013) (39)
Effects of rhIL-11 on normal dogs and after sublethal radiation. (1995) (38)
Ultraviolet irradiation of blood prevents transfusion-induced sensitization and marrow graft rejection in dogs. (1986) (38)
Hematopoietic stem cell transplantation for MDS. (2010) (38)
Marrow graft rejection and veno-occlusive disease of the liver in patients with aplastic anemia conditioned with cyclophosphamide and cyclosporine. (1986) (37)
Effect of antithymocyte globulin source on outcomes of bone marrow transplantation for severe aplastic anemia (2014) (37)
Discordant expression of AC133 and AC141 in patients with myelodysplastic syndrome (MDS) and acute myelogeneous leukemia (AML) (2000) (37)
Allogeneic bone marrow transplantation for secondary leukemia or myelodysplasia. (1999) (37)
Hematopoietic Cell Transplantation as Curative Therapy for Patients with Myelofibrosis: Long-Term Success in all Age Groups. (2015) (37)
Marrow transplantation for leukemia following fractionated total body irradiation. A comparative trial of methotrexate and cyclosporine. (1985) (36)
Allogeneic marrow transplantation following cyclophosphamide and escalating doses of hyperfractionated total body irradiation in patients with advanced lymphoid malignancies: a Phase I/II trial. (1995) (36)
High-dose total-body irradiation and autologous marrow reconstitution in dogs: dose-rate-related acute toxicity and fractionation-dependent long-term survival. (1981) (36)
Haemopoietic stem cell transplantation for advanced polycythaemia vera or essential thrombocythaemia (2001) (36)
Phase 1/2 Study of SB1518, a Novel JAK2/FLT3 Inhibitor, In the Treatment of Primary Myelofibrosis (2010) (36)
Current and Future Preparative Regimens for Bone Marrow Transplantation in Thalassemia a (1998) (36)
IMMUNOLOGIC RECOVERY IN HUMAN MARROW GRAFT RECIPIENTS GIVEN CYCLOSPORINE OR METHOTREXATE FOR THE PREVENTION OF GRAFT‐VERSUS‐HOST DISEASE (1984) (36)
Optimization of therapy for severe aplastic anemia based on clinical, biologic, and treatment response parameters: conclusions of an international working group on severe aplastic anemia convened by the Blood and Marrow Transplant Clinical Trials Network, March 2010. (2011) (35)
A Decision Analysis of Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation for Older Patients with De-Novo Myelodysplastic Syndrome (MDS): Early Transplantation Offers Survival Benefit in Higher-Risk MDS (2011) (35)
Factors Determining Responses to Azacitidine in Patients with Myelodysplastic Syndromes and Acute Myeloid Leukemia with Early Post-Transplantation Relapse: A Prospective Trial. (2017) (35)
Reduced expression of inducible gelatinase B/matrix metalloproteinase-9 in monocytes from patients with myelodysplastic syndrome: Correlation of inducible levels with the percentage of cytogenetically marked cells and with marrow cellularity. (2007) (35)
Stroma-dependent apoptosis in clonal hematopoietic precursors correlates with expression of PYCARD. (2009) (34)
Cytokines in Graft-Versus-Host Disease and the Graft-Versus-Leukemia Reaction (2001) (34)
Pro-apoptotic and anti-apoptotic effects of transferrin and transferrin-derived glycans on hematopoietic cells and lymphocytes. (2001) (34)
Methotrexate and cyclosporine for graft-vs.-host disease prevention: what length of therapy with cyclosporine? (1997) (34)
Batten's disease: failure of allogeneic bone marrow transplantation to arrest disease progression in a canine model (1990) (34)
Marrow transplantation for acute nonlymphocytic leukemia following therapy for Hodgkin's disease. (1987) (34)
Treatment of chronic myelomonocytic leukaemia by allogeneic marrow transplantation (2000) (34)
Optimization of transplant regimens for patients with myelodysplastic syndrome (MDS). (2005) (33)
DLA-identical bone marrow grafts after low-dose total body irradiation: the effect of canine recombinant hematopoietic growth factors. (1994) (33)
Characterization of host cells involved in resistance to marrow grafts in dogs transplanted from unrelated DLA-nonidentical donors. (1986) (33)
Phase II study of SB1518, an orally available novel JAK2 inhibitor, in patients with myelofibrosis. (2011) (32)
Alveolar macrophage kinetics and function after interruption of canine marrow function. (1982) (32)
Treatment of non‐Hodgkin's lymphoma with chemoradiotherapy and allogenic marrow transplantation (2007) (32)
Acute and chronic graft-versus-host disease: clinical manifestations, prophylaxis, and treatment. (1986) (32)
Myelodysplastic syndromes, version 2.2015. (2015) (31)
Human polyomavirus: lack of relationship of viruria to prolonged or severe hemorrhagic cystitis after bone marrow transplant. (1989) (31)
Nonspecific acid esterase activity as a marker for canine T lymphocytes. (1981) (31)
Prevention of Graft‐versus‐Host Disease (1995) (31)
Reduced dose intravenous immunoglobulin does not decrease transplant-related complications in adults given related donor marrow allografts. (1999) (31)
Marrow transplantation for leukemia and aplastic anemia: two controlled trials of a combination of methotrexate and cyclosporine v cyclosporine alone or methotrexate alone for prophylaxis of acute graft-v-host disease. (1987) (31)
Successful pregnancy after marrow transplantation for severe aplastic anemia and immunosuppression with cyclosporine. (1983) (31)
Autologous bone marrow transplantation for acute lymphoblastic leukemia. (1993) (30)
Pros and cons of splenectomy in patients with myelofibrosis undergoing stem cell transplantation (2001) (30)
Treatment of preleukemic syndromes with marrow transplantation. (1987) (30)
UV irradiation of lymphocytes triggers an increase in intracellular Ca2+ and prevents lectin-stimulated Ca2+ mobilization: evidence for UV- and nifedipine-sensitive Ca2+ channels. (1991) (30)
Risk factors for the development of secondary malignancies after marrow transplantation. (1993) (30)
Specific marrow ablation before marrow transplantation using an aminophosphonic acid conjugate 166Ho-EDTMP. (1992) (30)
Engraftment of dogs with Ia-positive marrow cells isolated by avidin-biotin immunoadsorption. (1987) (30)
Incidence of myelodysplastic syndromes within a nonprofit healthcare system in western Washington state, 2005–2006 (2010) (30)
Prevention of graft-versus-host disease by immunosuppressive agents after transplantation of DLA-nonidentical canine marrow. (1986) (29)
Flow Cytometry for Diagnosis and Assessment of Prognosis in Patients with Myelodysplastic Syndromes (2004) (29)
Marrow stroma in MDS: culprit or bystander? (2002) (29)
Effective ultraviolet irradiation of platelet concentrates in teflon bags (1990) (28)
Autologous marrow transplantation as consolidation therapy for canine lymphoma: efficacy and toxicity of various regimens of total body irradiation. (1985) (28)
MARROW TRANSPLANT STUDIES IN DOGS WITH MALIGNANT LYMPHOMA (1985) (28)
Marrow transplant experience for children with severe aplastic anemia. (1994) (28)
Transfusion‐induced graft‐versus‐host disease in patients with malignant lymphoma a case report and review of the literature (1990) (28)
Myelodysplastic syndromes: clinical practice guidelines in oncology. (2013) (28)
Effect of trimethoprim-sulfamethoxazole on hematological recovery after total body irradiation and autologous marrow infusion in dogs. (1979) (28)
Influence of post-methotrexate folinic acid rescue on regimen-related toxicity and graft-versus-host disease after allogeneic bone marrow transplantation. (1992) (27)
FACILITATION OF ENGRAFTMENT OF DLA‐NONIDENTICAL MARROW BY TREATMENT OF RECIPIENTS WITH MONOCLONAL ANTIBODY DIRECTED AGAINST MARROW CELLS SURVIVING RADIATION (1987) (27)
NCCN Task Force: Transfusion and iron overload in patients with myelodysplastic syndromes. (2009) (27)
Cytotoxic T lymphocyte antigen 4-immunoglobulin fusion protein combined with methotrexate/cyclosporine as graft-versus-host disease prevention in a canine dog leukocyte antigen-nonidentical marrow transplant model. (2000) (27)
Cyclosporine-associated renal dysfunction in marrow transplant recipients. (1985) (27)
Acute Graft-vs-Host Disease (2004) (26)
Proteomic classification of acute leukemias by alignment-based quantitation of LC-MS/MS data sets. (2012) (26)
The KDM2B- Let-7b -EZH2 Axis in Myelodysplastic Syndromes as a Target for Combined Epigenetic Therapy (2014) (26)
Ultraviolet B-induced loss of HLA class II antigen expression on lymphocytes is dose, time, and locus dependent. (1990) (26)
A population-based study of survival in patients with secondary myelodysplastic syndromes (MDS): impact of type and treatment of primary cancers (2007) (26)
Functional dendritic cells are required for transfusion-induced sensitization in canine marrow graft recipients. (1988) (25)
Cyclophosphamide-Based In Vivo T-Cell Depletion for HLA-Haploidentical Transplantation in Fanconi Anemia (2012) (25)
Blood or marrow? (2000) (25)
Prophylaxis and treatment of acute graft-versus-host disease: current state, implications of new immunopharmacologic compounds and future strategies to prevent and treat acute GVHD in high-risk patients. (1994) (25)
Hematopoietic stem cell transplantation in patients with myelodysplastic syndrome. (2000) (25)
Outcome following haematopoietic cell transplantation in patients with myelodysplasia and del (5q) karyotypes (2003) (24)
Increased cancer risk in canine radiation chimeras (1980) (24)
Acute lymphoblastic leukaemia after bone marrow transplantation for aplastic anaemia (1986) (24)
Marrow Transplantation for Thalassemia a (1985) (24)
B-cell lymphoma developing in the donor 9 years after donor-origin acute myeloid leukemia post bone marrow transplantation (2003) (24)
Mechanisms of tolerance in canine radiation chimeras. (1987) (24)
Cyclosporine or cyclosporine plus methylprednisolone for prophylaxis of graft-versus-host disease: A prospective, randomized trial (1997) (23)
Hematopoietic stem cell transplantation for myelodysplastic syndrome: a review. (2011) (23)
Acute-Phase Protein α1-Antitrypsin—A Novel Regulator of Angiopoietin-like Protein 4 Transcription and Secretion (2014) (23)
Uncertainty of Physicians and Patients in Medical Decision Making. (2017) (23)
ENGRAFTMENT OF DLA‐NONIDENTICAL UNRELATED CANINE MARROW AFTER HIGH‐DOSE FRACTIONATED TOTAL BODY IRRADIATION (1982) (23)
Failure of autologous marrow reconstitution after cytolytic treatment of marrow with anti-Ia monoclonal antibody. (1985) (23)
Myelodysplastic syndrome evolving from aplastic anemia treated with immunosuppressive therapy: efficacy of hematopoietic stem cell transplantation (2014) (23)
Major histocompatibility complex class II-mediated inhibition of hematopoiesis in long-term marrow cultures involves apoptosis and is prevented by c-kit ligand. (1995) (23)
Cyclosporin-A: effect on marrow engraftment and graft-versus-host disease in dogs. (1981) (22)
Use of a water-soluble busulfan formulation--pharmacokinetic studies in a canine model. (1995) (22)
NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 3.2022. (2022) (22)
Genetic factors rather than blast reduction determine outcomes of allogeneic HCT in BCR-ABL-negative MPN in blast phase. (2020) (22)
131I-Anti-CD45 Antibody Plus Fludarabine, Low-Dose Total Body Irradiation and Peripheral Blood Stem Cell Infusion for Elderly Patients with Advanced Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS). (2005) (22)
Marrow transplantation for severe aplastic anemia and thalassemia major. (1991) (22)
Growth in vitro of donor marrow cultured with recipient lymphocytes predicts the fate of marrow grafts in transfused DLA-identical dogs. (1979) (22)
Myeloablation by intravenous busulfan and hematopoietic reconstitution with autologous marrow in a canine model. (1999) (21)
Pneumatosis cystoides intestinalis following allogeneic marrow transplantation. (1983) (21)
Success of allogeneic marrow transplantation for children with severe aplastic anaemia (2012) (21)
Effect of race on outcomes after allogeneic hematopoietic cell transplantation for severe aplastic anemia (2011) (20)
Long-term follow-up of a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide for patients receiving allogenic marrow transplants during chronic phase of chronic myeloid leukemia. (1999) (20)
Effect of intravenous coadministration of human stroma cell lines on engraftment of long-term repopulating clonal myelodysplastic syndrome cells in immunodeficient mice (2013) (20)
Long Term Clinical Benefit of Lenalidomide (Revlimid) Treatment in Patients with Myelodysplastic Syndrome without Del 5q Cytogenetic Abnormalities. (2006) (20)
Late failure of autologous marrow grafts in lethally irradiated dogs given anti-class II monoclonal antibody. (1991) (20)
Prevention of Fas-mediated hepatic failure by transferrin (2004) (20)
Murine xenogeneic models of myelodysplastic syndrome: an essential role for stroma cells. (2014) (20)
Increased cancer risk in canine radiation chimeras. (1980) (20)
Acute and chronic graft-versus-host disease in dogs given hemopoietic grafts from DLA-nonidentical littermates. Two distinct syndromes. (1982) (20)
Eprenetapopt Plus Azacitidine After Allogeneic Hematopoietic Stem-Cell Transplantation for TP53-Mutant Acute Myeloid Leukemia and Myelodysplastic Syndromes (2022) (20)
Is race a risk factor for allogeneic marrow transplantation? (1986) (20)
Total body irradiation and autologous marrow transplantation as consolidation therapy for spontaneous canine lymphoma in remission. (1979) (20)
Effect of recombinant canine granulocyte-macrophage colony-stimulating factor on hematopoietic recovery after otherwise lethal total body irradiation. (1994) (20)
Allogeneic hematopoietic cell transplantation for advanced polycythemia vera and essential thrombocythemia. (2012) (19)
Conditioning Intensity and Peri-Transplant Flow Cytometric MRD Dynamics in Adult AML. (2022) (19)
Hematopoietic cell transplantation for adult patients with myelodysplastic syndromes and myeloproliferative disorders. (2003) (19)
Hemopoietic cell transplantation as curative therapy of myelodysplastic syndromes and myeloproliferative disorders. (2006) (19)
Graft-versus-host disease: host and donor views. (1993) (19)
Allogeneic hematopoietic cell transplantation for patients with myelofibrosis (2009) (19)
Myeloid Malignancies and the Marrow Microenvironment: Some Recent Studies in Patients with MDS. (2009) (19)
Hematopoietic reconstitution and prevention of graft-versus-host disease with UVB-irradiated haploidentical murine spleen and marrow cells. (1991) (19)
HLA-DR-mediated signals for hematopoiesis and induction of apoptosis involve but are not limited to a nitric oxide pathway. (1997) (19)
Transplantation of allogeneic T cells alters iron homeostasis in NOD/SCID mice. (2009) (19)
Preliminary results of prospective randomized trials comparing methotrexate and cyclosporine for prophylaxis of graft-vs.host-disease after HLA-identical marrow transplantations (1983) (18)
In vitro tests correlating with presence or absence of graft-vs-host disease in DLA nonidentical canine radiation chimeras: evidence that clonal abortion maintains stable graft-host tolerance. (1980) (18)
Chelerythrin activates caspase‐8, downregulates FLIP long and short, and overcomes resistance to tumour necrosis factor‐related apoptosis‐inducing ligand in KG1a cells (2003) (18)
Dose rate-dependent marrow toxicity of TBI in dogs and marrow sparing effect at high dose rate by dose fractionation. (1999) (18)
Long-term follow-up of a randomized trial of graft-versus-host disease prevention by methotrexate/cyclosporine versus methotrexate alone in patients given marrow grafts for severe aplastic anemia. (1994) (18)
Differential responses of FLIPLong and FLIPShort-overexpressing human myeloid leukemia cells to TNF-alpha and TRAIL-initiated apoptotic signals. (2008) (18)
Indications for and current results with allogeneic hematopoietic cell transplantation in patients with myelofibrosis. (2011) (17)
Photoinactivation of lymphohemopoietic cells: studies in transfusion medicine and bone marrow transplantation. (1992) (17)
Marrow transplantation for hepatitis-associated aplastic anemia: a follow-up of long-term survivors. (1996) (17)
Identification of DJ-1/PARK-7 as a determinant of stroma-dependent and TNF-alpha-induced apoptosis in MDS using mass spectrometry and phosphopeptide analysis. (2010) (17)
Dose rate-dependent sparing of the gastrointestinal tract by fractionated total body irradiation in dogs given marrow autografts. (1998) (17)
Effect of recombinant canine granulocyte-macrophage colony-stimulating factor on hematopoietic recovery after otherwise lethal total body irradiation (1994) (17)
Canine pluripotent hematopoietic stem cells and CFU-GM express Ia-like antigens as recognized by two different class II-specific monoclonal antibodies (1987) (17)
Abnormalities of the alphabeta T-cell receptor repertoire in advanced myelodysplastic syndrome. (2010) (17)
Acute Graft-versus-Host Disease (2008) (17)
Tacrolimus (FK506) and methotrexate regimens to prevent graft-versus-host disease after unrelated dog leukocyte antigen (DLA) nonidentical marrow transplantation. (1996) (16)
Hemopoietic stem cell transplantation for myelodysplastic syndrome (2000) (16)
Long-term follow-up of a controlled trial comparing a combination of methotrexate plus cyclosporine with cyclosporine alone for prophylaxis of graft-versus-host disease in patients administered HLA-identical marrow grafts for leukemia. (1992) (16)
Long-term follow-up of three controlled trials comparing cyclosporine versus methotrexate for graft-versus-host disease prevention in patients given marrow grafts for leukemia [letter] (1992) (16)
Ultrastructural localization of stem cell factor in canine marrow-derived stromal cells. (1995) (16)
Transfusions with a tan (1989) (16)
Cyclosporine (CSP)or CSP plus methylprednisolone for graft-versus-host disease prophylaxis in patients with high-risk lymphohemopoietic malignancies: long-term follow-up of a randomized trial. (2000) (16)
Allogeneic Hematopoietic Cell Transplantation in Patients Aged 50Years or Older with Severe Aplastic Anemia. (2019) (16)
New Strategies for Prevention and Treatment of Graft-versus-Host Disease and for Induction of Graft-versus-Leukemia Effects (2003) (16)
Thalidomide for treatment of patients with chronic graft-versus-host disease (2000) (16)
Cyclosporine-induced apoptosis in CD4+ T lymphocytes and computer-simulated analysis: modeling a treatment scenario for HIV infection. (1995) (15)
Two monoclonal antibodies (DLy-1 and DLy-6) directed against canine lymphocytes. (1982) (15)
Treatment-related myelodysplastic syndrome: molecular characteristics and therapy (2011) (15)
Transplant Conditioning with Treosulfan/Fludarabine with or without Total Body Irradiation: A Randomized Phase II Trial in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia. (2017) (15)
Rescue from anti-MHC class II antibody-mediated marrow graft failure by c-kit ligand. (1994) (15)
RECOGNITION OF TARGET CELL DETERMINANTS ASSOCIATED WITH DLA‐D‐LOCUS‐ENCODED ANTIGENS BY CANINE CYTOTOXIC LYMPHOCYTES (1985) (15)
Gene Expression Patterns in Myelodyplasia Underline the Role of Apoptosis and Differentiation in Disease Initiation and Progression (2008) (15)
LONG‐TERM STABLE MIXED CHIMAERISM FOLLOWING ALLOGENEIC MARROW TRANSPLANTATION FOR SEVERE APLASTIC ANAEMIA (1990) (15)
Mutational analysis in serial marrow samples during azacitidine treatment in patients with post-transplant relapse of acute myeloid leukemia or myelodysplastic syndromes (2017) (15)
Hematopoietic stem cell transplantation for myelofibrosis. (2005) (14)
Allogeneic hemopoietic stem cell transplantation in patients with myelodysplastic syndrome or myelofibrosis (2002) (14)
Etoposide, cyclophosphamide and fractionated total body irradiation as a preparative regimen for marrow transplantation in patients with advanced hematological malignancies: a phase I study. (1992) (14)
Allogeneic hematopoietic cell transplantation for MDS: for whom, when and how? (2012) (14)
Prevention of chronic GVHD. (2008) (14)
Clinical Efficacy and Safety of Oral Decitabine/Cedazuridine in 133 Patients with Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) (2020) (14)
Cyclosporin-A abrogates transfusion-induced sensitization and prevents marrow graft rejection in DLA-identical canine littermates. (1982) (14)
Differential effects of bexarotene on intrinsic and extrinsic pathways in TRAIL-induced apoptosis in two myeloid leukemia cell lines (2007) (14)
Modification of allointeractions after blood transfusion and marrow transplantation by ultraviolet light. (1992) (14)
REGRESSION OF ANDROGEN‐RELATED HEPATIC TUMORS IN PATIENTS WITH FANCONI'S ANEMIA FOLLOWING MARROW TRANSPLANTATION (1984) (14)
Marrow graft rejection in DLA-identical canine littermates: antigens involved are expressed on leukocytes and skin epithelial cells but probably not on platelets and red blood cells. (1979) (13)
Monoclonal antibody to human cytotoxic-suppressor T-lymphocytes cross-reacts with canine lymphocytes and inhibits cell-mediated lympholysis of canine cells. (1985) (13)
Methods for assessment of graft-versus-host disease. (1998) (13)
Hematopoietic cell transplantation for myelodysplastic syndrome. (2015) (13)
Secondary malignancies after marrow transplantation for leukemia or aplastic anemia. (1994) (13)
Major histocompatibility complex class II expression is required for posttransplant immunological but not hemopoietic reconstitution in mice. (1994) (13)
Severe aplastic anemia associated with chronic mucocutaneous candidiasis. Immunologic and hematologic reconstitution after allogeneic bone marrow transplantation. (1986) (13)
Retrovirus-Mediated Gene Transduction Into Canine Peripheral Blood Repopulating Cells (1994) (13)
Transplant Decisions in Patients with Myelofibrosis: Should Mutations Be the Judge? (2017) (13)
Induction of negative regulators of haematopoiesis in human bone marrow cells by HLA-DR cross-linking. (1999) (13)
MARROW GRAFTS BETWEEN PHENOTYPICALLY DLA‐IDENTICAL AND HAPLOIDENTICAL UNRELATED DOGS: ADDITIONAL ANTIGENS CONTROLLING ENGRAFTMENT ARE NOT DETECTED BY CELL‐MEDIATED LYMPHOLYSIS (1982) (13)
Secondary cytogenetic abnormalities in core-binding factor AML harboring inv(16) vs t(8;21). (2021) (13)
SELECTIVE INHIBITION OF THE CANINE MIXED LYMPHOCYTE RESPONSE BY HLA‐DR AND DP‐REACTIVE MONOCLONAL ANTIBODIES (1988) (13)
ENGRAFTMENT OF DLA‐NONIDENTICAL BONE MARROW FACILITATED BY RECIPIENT TREATMENT WITH ANTI‐CLASS II MONOCLONAL ANTIBODY AND METHOTREXATE (1987) (13)
Deciding on transplantation for myelofibrosis: setting the record straight. (2004) (13)
Purified canine monocytes fail to confer concanavalin-A responsiveness to accessory-cell-depleted lymphocytes. (1984) (13)
Homing and immunogenicity of murine stromal cells transfected with xenogeneic MHC class II genes. (1995) (13)
Treatment of refractory ITP and Evans syndrome by haematopoietic cell transplantation: is it indicated, and for whom? (2016) (13)
Canine lymphocyte subpopulations. (1980) (13)
Marrow graft studies in dogs. (1980) (12)
Stem-cell transplantation for myelofibrosis. (2001) (12)
Parenteral nutrition in marrow transplant recipients after discharge from the hospital. (1983) (12)
PHARMACOLOGIC, TOXICOLOGIC, AND MARROW TRANSPLANTATION STUDIES IN DOGS GIVEN SUCCINYL ACETONE (1992) (12)
Early Mixed Lymphoid Donor/Host Chimerism is Associated with Improved Transplant Outcome in Patients with Primary or Secondary Myelofibrosis. (2020) (12)
Use of iodine-131-labeled anti-immune response-associated monoclonal antibody as preparative regimen prior to bone marrow transplantation: initial dosimetry. (1987) (12)
Protection of human and murine hepatocytes against Fas-induced death by transferrin and iron (2006) (12)
Gamma radiation of blood products prevents rejection of subsequent DLA-identical marrow grafts. Tolerance versus abrogation of sensitization to non-DLA antigens. (1996) (12)
Impact of clinical, cytogenetic, and molecular profiles on long-term survival after transplantation in patients with chronic myelomonocytic leukemia (2019) (12)
Graft-versus-host disease prophylaxis with methotrexate/cyclosporine in children with severe aplastic anemia treated with cyclophosphamide and HLA-identical marrow grafts. (1991) (11)
Transplantation for myelodysplastic syndrome in the era of hypomethylating agents (2012) (11)
Hematopoietic cell transplantation (2006) (11)
Transplantation conditioning regimens: can we say it better? (2009) (11)
Toxicity trial of prophylactic 9-[2-hydroxy-1-(hydroxymethyl)ethoxymethyl]guanine (ganciclovir) after marrow transplantation in dogs (1988) (11)
Cluster formation of canine dendritic cells and lymphocytes is calcium dependent and not inhibited by cyclosporine. (1990) (11)
In vivo radioprotective effect of AcSDKP on canine myelopoiesis (1997) (11)
Lack of cytoprotective effect of amifostine following HLA-identical sibling transplantation for advanced myelodysplastic syndrome (MDS): a pilot study (2003) (11)
Transferrin fails to provide protection against Fas-induced hepatic injury in mice with deletion of functional transferrin-receptor type 2 (2008) (10)
SPECIFIC TOLERANCE AND IMMUNOCOMPETENCE IN HAPLOIDENTICAL, BUT NOT IN COMPLETELY ALLOGENEIC, CANINE CHIMERAS TREATED WITH METHOTREXATE AND CYCLOSPORINE (1987) (10)
Graft-versus-host disease and the development of late complications. (1994) (10)
Transplantation for myelodysplastic syndromes 2013 (2013) (10)
Marrow transplantation for severe aplastic anemia: the Seattle experience. (1984) (10)
No telomere shortening in marrow stroma from patients with MDS (2009) (10)
Hematopoietic cell transplantation for patients with myelodysplastic syndromes (MDS): when, how and for whom? (2008) (10)
Impact of Conditioning Intensity and Genomics on Relapse After Allogeneic Transplantation for Patients With Myelodysplastic Syndrome (2020) (10)
Upregulation of interleukin-10 and inhibition of alloantigen responses by transferrin and transferrin-derived glycans. (2000) (10)
Transfusions shortly before HLA-matched marrow transplantation for leukemia are associated with a decrease in chronic graft-versus-host disease. (1991) (10)
Phase II Trial of Eprenetapopt (APR-246) in Combination with Azacitidine (AZA) As Maintenance Therapy for TP53 Mutated AML or MDS Following Allogeneic Stem Cell Transplantation (SCT) (2021) (10)
Transplant strategies for patients with myelodysplastic syndromes (2006) (10)
Effector cells of graft-versus-host disease, host resistance, and the graft-versus-leukemia effect: summary of a workshop on bone marrow transplantation. (1987) (10)
Impact of Copy Neutral Loss of Heterozygosity and Total Genome Aberrations on Survival in Myelodysplastic Syndrome (2017) (10)
Differential sensitivity of human leukocyte subpopulations to ultraviolet light. (1989) (10)
Facilitation of DLA-incompatible marrow grafts by donor-specific serum transferrin? (1996) (10)
Apoptosis and anti-apoptotic mechanisms in the progression of MDS (2007) (9)
Pomalidomide Therapy in Anemic Patients with Myelofibrosis: Results from a Phase-2 Randomized Multicenter Study (2008) (9)
Recognition of major histocompatibility complex class II antigens by two anti-HLA-DR monoclonal antibodies on canine marrow cells correlates with effects on in vitro and in vivo hematopoiesis. (1999) (9)
DLA-D-specific suppressor cells characterized by monoclonal antibodies. (1985) (9)
Allogeneic Hematopoietic Cell Transplantation in Patients with Myelodysplastic Syndrome and Concurrent Lymphoid Malignancy (2011) (9)
What is in a name? Refined diagnostic criteria for prognostic assessment in myelodysplastic syndrome (MDS). (2004) (9)
Hematopoietic stem cell transplantation for older patients with myelodysplastic syndromes. (2013) (9)
Inhibition of the enzyme purine nucleoside phosphorylase (PNP) reduces refractoriness to transfused platelets in a dog model (1990) (9)
High IGFBP-3 levels in marrow plasma in early-stage MDS: effects on apoptosis and hemopoiesis (2005) (9)
Canine pluripotent hematopoietic stem cells and CFU-GM express Ia-like antigens as recognized by two different class II-specific monoclonal antibodies. (1987) (9)
Fanconi anemia type C-deficient hematopoietic cells are resistant to TRAIL (TNF-related apoptosis-inducing ligand)-induced cleavage of pro-caspase-8. (2004) (9)
Major histocompatibility complex class II molecules, hemopoiesis and the marrow microenvironment. (1993) (9)
Stem cell factor-induced expression of p27kip-1 during hematopoietic differentiation. (1995) (9)
Current status of allogeneic hematopoietic cell transplantation for MDS. (2012) (8)
HLA-matched sibling transplantation for severe aplastic anemia: impact of HLA DR15 antigen status on engraftment, graft-versus-host disease, and overall survival. (2012) (8)
Inhibition of canine NK activity by anti-CD18 monoclonal antibody, UV irradiation and cyclosporine. (1993) (8)
Flow cytometric detection of nonneoplastic antigenic polymorphisms of donor origin after allogeneic marrow transplant (2004) (8)
Inhibition of Cluster Formation and Lymphocyte Proliferation by Anti‐Fibronectin Antiserum (1991) (8)
Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q) (2017) (8)
A canine model of induced purine nucleoside phosphorylase deficiency. (1986) (8)
Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome: the past decade (2012) (8)
Inhibition of hematopoiesis in long-term marrow cultures established on adherent layers from AcSDKP-treated dogs. (1995) (8)
Management of Infections (1988) (8)
A toxicity study of trimetrexate used in combination with cyclosporine as acute graft-versus-host disease prophylaxis in HLA-mismatched, related donor bone marrow transplants. (1995) (8)
Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome: Current Status (2012) (8)
Myelodysplastic SyndromesPractice Guidelines in Oncology (2011) (8)
Severe Refractory Immune Thrombocytopenia Successfully Treated with High-Dose Pulse Cyclophosphamide and Eltrombopag (2015) (8)
Therapy for Hematologic Cancers in Older Patients, Quality of Life, and Health Economics: Difficult Decisions. (2015) (7)
Flow cytometric detection of nonneoplastic antigenic polymorphisms of donor origin after allogeneic marrow transplant: a report of two cases. (2004) (7)
The National MDS Natural History Study: design of an integrated data and sample biorepository to promote research studies in myelodysplastic syndromes (2019) (7)
Mechanisms of tolerance in marrow transplantation. (1984) (7)
International Working Group Scores Predict Post-Transplant Outcomes In Patients with Myelofibrosis (2010) (7)
Transplantation and aging. (2006) (7)
PULMONARY BRONCHOALVEOLAR CELL AND PROTEIN KINETICS IN DOGS GIVEN TOTAL‐BODY IRRADIATION, AUTOLOGOUS MARROW GRAFTS, AND METHOTREXATE (1984) (7)
Second Allogeneic Hematopoietic Cell Transplantation for Patients with Fanconi Anemia and Bone Marrow Failure. (2015) (7)
Allogeneic transplantation, Fas signaling, and dysregulation of hepcidin. (2013) (7)
Is there a better way to deliver total body irradiation? (1992) (7)
Identification of immunoglobulin-secreting cells among canine peripheral blood mononuclear cells by the protein A hemolytic plaque assay. (1983) (7)
Total-Body Irradiation in Bone Marrow Transplantation (1990) (6)
Erythroid colony stimulating and inhibiting cells in peripheral blood of transfused dogs: separation of function by velocity sedimentation. (1979) (6)
Hematologic malignancies : myelodysplastic syndromes (2006) (6)
Canine osteosarcoma: Results of amputation with and without adjuvant immunotherapy (1978) (6)
Role of hematopoietic stem cell transplantation in patients with myeloproliferative disease. (2014) (6)
Quantitative analysis of glycans, related genes, and proteins in two human bone marrow stromal cell lines using an integrated strategy. (2015) (6)
The Biology of Chronic Graft-Versus-Host Disease (1985) (6)
Immunogenetic aspects of a canine breeding colony. (1985) (6)
Hematopoietic cell transplantation for chronic myeloproliferative disorders (2006) (6)
Contributions of the dog model in marrow transplantation (1985) (6)
Jumping translocations in myelodysplastic syndromes. (2016) (6)
Use of trimetrexate for the prevention of graft-versus-host disease. (1989) (6)
DLA-identical marrow grafts after low-dose total-body irradiation. Addition of viable donor peripheral blood mononuclear cells does not enhance engraftment. (1995) (6)
Spliceosome mutations are common in persons with myeloproliferative neoplasm-associated myelofibrosis with RBC-transfusion-dependence and correlate with response to pomalidomide (2020) (6)
Failure of anti-Ia monoclonal antibody to abrogate transfusion-induced sensitization and prevent marrow graft rejection in DLA-identical canine littermates. (1988) (6)
Prevention of graft failure in patients with aplastic anemia. (1993) (6)
Treatment ethics, quality of life and health economics in the management of hematopoietic malignancies in older patients (2015) (6)
CDK-inhibitor independent cell cycle progression in an experimental haematopoietic stem cell leukaemia despite unaltered Rb-phosphorylation (1999) (5)
Myelodysplastic syndromes. (2011) (5)
Long-term follow-up of three controlled trials comparing cyclosporine versus methotrexate for graft-versus-host disease prevention in patients given marrow grafts for leukemia. (1992) (5)
GVHD-free with Campath? (2011) (5)
Oral Decitabine/Cedazuridine in Patients with Lower Risk Myelodysplastic Syndrome: A Longer-Term Follow-up of from the Ascertain Study (2021) (5)
Functional dichotomy of canine thoracic duct lymphocytes: proliferation in mixed leukocyte culture and unresponsiveness to plant lectins. (1981) (5)
Soluble TNF receptor fusion protein (TNFRrFc; Enbrel) in the treatment of patients with myelodysplastic syndrome (MDS) (2000) (5)
Treosulfan-based conditioning is feasible and effective for cord blood recipients: a phase 2 multicenter study. (2020) (5)
Phenotypic and functional alterations of recipient lymphocytes after transfusion of UV-irradiated and normal blood--implications for marrow transplantation. (1987) (5)
Safety and Tolerability of Fedratinib (FEDR), an Oral Inhibitor of Janus Kinase 2 (JAK2), in Patients with Intermediate- or High-Risk Myelofibrosis (MF) Previously Treated with Ruxolitinib (RUX): Results from the Phase 3b FREEDOM Trial (2021) (5)
Methods for assessment of graft-versus-host disease [5] (multiple letters) (1998) (5)
Failure of interleukin-1 and granulocyte-macrophage colony-stimulating factor to enhance allogeneic marrow engraftment and survival in irradiated dogs. (1995) (5)
Allogeneic transplant of canine peripheral blood stem cells mobilized by recombinant canine hematopoietic growth factors. (1996) (5)
Resistance to marrow grafts in dogs mediated by antigens close to but not identical with DLA-A, B, and C and overcome by infusion of thoracic-duct lymphocytes. (1979) (5)
A novel retroviral mutagenesis screen identifies prognostic genes in RUNX1 mediated myeloid leukemogenesis (2015) (4)
Bone marrow and organ transplantation edited by Shimon Slavin, Elsevier 1984. $163.50/Dfl 425.00 (xv + 651 pages) ISBN 0 444 80556 7. (1985) (4)
Fibronectin Is Present on B‐Cells but not on OKT 3‐Positive T‐Lymphocytes or LEU 11‐Positive Natural Killer Cells (1986) (4)
Elevated TWIST1 expression in myelodysplastic syndromes/ acute myeloid leukemia reduces efficacy of hypomethylating therapy with decitabine. (2020) (4)
Response:Solid cancers after allogeneic hematopoietic cell transplantation (2009) (4)
Succinyl acetone plus methotrexate as graft-versus-host disease prophylaxis in DLA-haploidentical canine littermate marrow grafts. (1992) (4)
What role for 15-deoxyspergualin in enhancing engraftment of unrelated, histoincompatible canine marrow grafts and preventing graft-versus-host disease? (1993) (4)
Soluble TNF receptor fusion protein (etanercept) for the treatment of myelodysplastic syndrome (2002) (4)
Allogeneic Hematopoietic Cell Transplantation for Patients with Myelodysplastic Syndrome and Myeloproliferative Disorders (2008) (4)
Prophylaxis and treatment of acute graft-versus-host disease (1994) (4)
Treatment of Patients with Steroid Refractory Acute Graft Vs Host Disease (SR-GvHD): A Matched Paired Analysis of Anti-CD26 (Begelomab) Compared to Other Treatment (2016) (4)
Haploidentical bone marrow transplantation in patients with relapsed or refractory severe aplastic anaemia in the USA (BMT CTN 1502): a multicentre, single-arm, phase 2 trial. (2022) (4)
Canine osteosarcoma failure of intravenous or intralesional BCG as adjuvant immunotherapy (1981) (4)
Facilitation of engraftment of DLA-nonidentical marrow by treatment of the recipient with monoclonal anti-Ia antibody (1985) (4)
Early pulmonary recurrence of non-Hodgkin's lymphoma after autologous marrow transplantation: evidence for reinfusion of lymphoma cells? (1995) (4)
The biology of graft rejection in a canine model of marrow transplantation. (1987) (4)
Allogeneic Hematopoietic Cell Transplantation and Other Expensive Cellular Therapies: A Miracle for the Few but Off Limits to Many? (2019) (4)
Outcomes of Patients With Therapy-Related MDS After Chemoimmunotherapy for Chronic Lymphocytic Leukemia Compared With Patients With De Novo MDS: A Single-Institution Experience. (2019) (4)
Allogeneic Hematopoietic Cell Transplantation in Patients aged 50 years or older with Severe Aplastic Anemia (2019) (4)
Effect of recombinant canine stem cell factor, a c-kit ligand, on hematopoietic recovery after DLA-identical littermate marrow transplants in dogs. (1997) (4)
MHC antigens and haemopoiesis. (1994) (4)
Bone marrow storage and processing: is it time to set standards? (1990) (4)
Corticotropin releasing factor with or without methotrexate for prevention of graft-versus-host disease in DLA-nonidentical unrelated canine marrow grafts. (1995) (4)
Body weight and outcome of hematopoietic stem cell transplantation. (1998) (4)
Impact of the Novel 5-Group Cytogenetic Risk Classification of MDS on Outcome After Allogeneic Hematopoietic Cell Transplantation (HCT) (2011) (4)
MDS Marrow Stroma Is Characterized by Distinct Epigenetic Alterations (2008) (4)
ANALYSIS OF ALLOREACTIVE AND CYTOTOXIC CANINE LYMPHOCYTES AND THEIR PRECURSORS WITH MURINE MONOCLONAL ANTIBODIES: Expression of Ia Antigens on Cytotoxic Effector Cells (1983) (4)
Major histocompatibility complex class II-mediated inhibition of hemopoiesis in vitro and in vivo is abrogated by c-kit ligand. (1995) (4)
Monoclonal antibodies to canine differentiation antigens. (1987) (3)
Control of hematopoiesis and apoptosis in MDS: more than FLIPing the coin. (2007) (3)
Failure of recombinant stem cell factor to enhance engraftment of L-leucyl-L-leucine methyl ester treated canine marrow after irradiation. (1996) (3)
Prediction of Acute Graft versus Host Disease and Relapse by Endogenous Metabolomic Compounds in Patients Receiving Personalized Busulfan-Based Conditioning. (2020) (3)
Characteristics and Clinical Outcome of Patients with Clonal Cytopenias of Undetermined Significance: A Large Retrospective Multi-Center International Study (2021) (3)
Hematopoietic Cell Transplantation for Older Patients with MDS (2014) (3)
Hematopoietic Cell Transplantation for Myelodysplastic Syndrome and Myeloproliferative Disorders (2009) (3)
The message is not the median! (2004) (3)
Results of Allogeneic Marrow Transplantation in Patients Transplanted for Acute Leukemia: A Long-Term Follow-Up (1986) (3)
Immunosuppression for marrow transplantation (1985) (3)
Antithymocyte globulin followed by cyclosporine for the treatment of acute GVHD in patients given HLA-identical or -nonidentical marrow grafts (1986) (3)
Cancer Cell SRSF2 Mutations Contribute to Myelodysplasia Through Mutant-Specific Effects on Exon Recognition (2015) (3)
Secondary Malignancies after Allogeneic or Autologous Marrow Transplantation (2000) (3)
Targeted Sequencing of 7 Genes Can Help Reduce Pathologic Misclassification of MDS (2020) (3)
An anti-CD44 antibody does not enhance engraftment of DLA-identical marrow after low-dose total body irradiation. (1996) (3)
DLA-nonidentical unrelated marrow grafts after high-dose total body irradiation: granulocyte colony-stimulating factor treatment after transplant does not enhance engraftment [letter] (1996) (3)
Neuroimmunomodulation and aging: a role for transferrin and the hypothalamus/thymus axis. (2013) (3)
Stimulation of canine lymphocyte subpopulations separated nonlytically by monoclonal anti-T and polyclonal Anti-B cell antibodies (1982) (3)
Modification of immunogenicity of transfusion products. (1986) (3)
MHC class II and negative regulators of hematopoiesis. (1998) (3)
Renal Cyclosporine Clearance in Marrow Transplant Recipients: Age‐Related Variation (1986) (3)
Graft-versus-host disease: facts and thoughts on recent developments (2000) (3)
Effect of cyclosporin A (CyA) on marrow engraftment in vivo and on hematopoiesis in vitro (1980) (3)
FAILURE OF ANTITHYMOCYTE SERUM POSTGRAFTING TO OVERCOME “RESISTANCE” TO DLANONIDENTICAL CANINE MARROW GRAFTS1 (1988) (3)
Myelodysplastic Syndrome Marrow Stroma Shows Widespread Aberrant Hypermethylation That Is Abrogated By Treatment with Dnmt Inhibitors (2014) (2)
Effect of anti-Ia monoclonal antibodies on in vitro immune responses of canine cells. (1988) (2)
Minimal Identifiable Disease and the Role of Conditioning Intensity in Hematopoietic Cell Transplantation for MDS and AML evolving from MDS (2016) (2)
Marrow transplantation in preleukemia. (1986) (2)
Not all patients with AML over 60 years of age should be offered early allogeneic stem cell transplantation (2021) (2)
Survival of Allogeneic Stem Cell Transplantation Vs Conventional Therapies per DIPSS Stratification in Patients with Primary Myelofibrosis Younger Than 65 Years: A Retrospective Analysis on 673 Patients (2014) (2)
Disease Progression, Treatment Patterns, Hospitalization, and Clinical Outcomes of Patients with Acute Graft-Versus-Host Disease (aGVHD) after Allogeneic Hematopoietic Stem Cell Transplant (HSCT): A Multicenter Chart Review (2020) (2)
Neutralization of stem cell factor in vitro and in vivo: dose-dependent inhibition of stromal cells and induction of granulocyte/monocyte differentiation (1996) (2)
SRSF2 Mutations Impair Hematopoietic Differentiation By Altering Exonic Splicing Enhancer Preference (2014) (2)
Low Toxicity and Mortality with Reversed-Order Conditioning (Cyclophosphamide Followed by Targeted Intravenous Busulfan) in Allogeneic Hematopoietic Cell Transplantation: Preliminary Results of a Prospective Clinical Trial. (2009) (2)
Predictive facts and prevention of acute graft-versus-host disease (1988) (2)
Side Effects of Conditioning Regimens (1992) (2)
P1042: SAFETY AND TOLERABILITY RESULTS FROM THE PHASE 3B FREEDOM TRIAL OF FEDRATINIB (FEDR), AN ORAL, SELECTIVE JAK2 INHIBITOR, IN PATIENTS WITH MYELOFIBROSIS (MF) PREVIOUSLY TREATED WITH RUXOLITINIB (RUX) (2022) (2)
Donor Treatment with α1 Anti-Trypsin (AAT) Mitigates Gvhd and Increases Survival While Sparing GVL Effects (2012) (2)
Hla-dr-initiated inhibition of hematopoiesis involves apoptosis via a fas/fas-ligand pathway (1996) (2)
JAK Inhibitors and Allogeneic Stem Cell Transplantation for Myelofibrosis (2015) (2)
[Bone marrow transplantation in chronic myeloid leukemia]. (1985) (2)
Comparison of 5-Azacytidine Versus Allogeneic Hematopoietic Cell Transplantation In Elderly (≥ 60 years) Patients with De Novo High-Risk MDS - a Retrospective Matched Pair Analysis (2010) (2)
Comparative Analysis of Total Body Irradiation (TBI)-Based and Non-TBI-Based Myeloablative Conditioning for Acute Myeloid Leukemia in Remission with and without Measurable Residual Disease (2019) (2)
Suppressor and cytotoxic cells in DLA nonidentical canine radiation chimeras given cyclosporine and methotrexate as prophylaxis for graft-versus-host disease (1983) (2)
Functional subsets of peripheral blood mononuclear cells in transfused dogs separated by size with the fluorescence activated cell sorter. (1980) (2)
Prediction of Busulfan Clearance by Predose Plasma Metabolomic Profiling (2022) (2)
Erythropoietic reserve in marrow-transplanted dogs. (1986) (2)
Germline-somatic JAK2 interactions are associated with clonal expansion in myelofibrosis (2022) (2)
Delay of radiation-induced decline and recovery of hematopoiesis following treatment with anti-HLA-DR antibody. (1996) (2)
Elevated TWIST1 expression in myelodysplastic syndromes/ acute myeloid leukemia reduces efficacy of hypomethylating therapy with decitabine (2020) (2)
Role of radiation-resistant large granular lymphocytes in the rejection of unrelated DLA-nonidentical marrow grafts in dogs. (1987) (2)
Defective CD4+ T-lymphocyte reconstitution in major histocompatibility complex class II-deficient transplant models. (1995) (2)
Arsenic Trioxide (ATO) Induced Apoptosis in Myelodysplastic Syndrome (MDS): The Role of TNFa and NFkB. (2004) (2)
Two monoclonal antibodies recognizing subpopulations of canine T lymphocytes with or without suppressor/cytotoxic functions. (1987) (1)
Cyclosporine (CSP) or CSP plus methylprednisolone for graft-versus-host- disease prophylaxis in patients with high-risk lymphohemopoietic malignancies (2000) (1)
Efficacy and tolerability of lenalidomide (LEN) in patients (pts) 75 and older versus those younger than 75 with RBC transfusion-dependent low/int-1-risk MDS and del 5q. (2012) (1)
Immunosuppressive agents for prevention of graft-versus-host disease (1995) (1)
Wnt / ß-catenin activation by epigenetically aberrant stroma drives myelodysplastic syndrome (2017) (1)
MDS Stem Cell Biology (2013) (1)
The canine major histocompatibility complex. Supertypic specificities defined by the Primed Lymphocyte Test (PLT) (2004) (1)
Prospective Phase II Multicenter Study of Conditioning with Treosulfan, Fludarabine and Low-Dose (2 Gy) Total Body Irradiation Followed by Hematopoietic Cell Transplantation From Related or Unrelated Donors for Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome (2012) (1)
Clonal Cytopenias of Undetermined Significance Are Common in Cytopenic Adults Evaluated for MDS in the National MDS Study (2019) (1)
Disruption of Iron Regulation after Radiation and Donor Cell Infusion. (2016) (1)
Cyclosporin A (CYA) (1982) (1)
Pre-transplant Neutropenia Is Associated with Poor Risk Cytogenetic Features and Increased Infection-related Mortality in Patients with Myelodysplastic Syndromes (2008) (1)
Risk factors associated with increased grades III-IV acute graft-versus-host disease (GVHD) after allogeneic hematopoietic cell transplantation (HCT) (2006) (1)
Red blood cell transfusion-dependence and outcome after allogeneic peripheral blood stem cell transplantation in patients with de novo myelodysplastic syndromes (MDS) (2009) (1)
Hematopoietic Bone Marrow Transplantation (BMT) for Patients with High-Risk Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS) Using HLA-Haploidentical Related Donors: A Trial Using Radiolabeled Anti-CD45 Antibody Combined with Immunosuppression Befor (2012) (1)
[Biologic changes in MDS-L cell line induced by As2O3 and/or TRAIL]. (2004) (1)
Efficacy of Oral Decitabine/Cedazuridine (ASTX727) in the CMML Subgroup from the Ascertain Phase 3 Study (2021) (1)
Anti-CD45 Radioimmunotherapy Followed By Haploidentical Allogeneic Hematopoietic Cell Transplantation for Advanced Acute Leukemia or High-Risk MDS (2017) (1)
Utility of Treatment-Related Mortality (TRM) Score to Predict Outcomes of Adults with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation (2022) (1)
Individuals, Boundaries, and Graft-versus-Host Disease (2020) (1)
Treatment of therapy-related MDS--it is worth a try! (2012) (1)
Hemopoietic cell transplantation for myelodysplastic syndromes. (2003) (1)
Should skin grafts be used to test for tolerance? (2006) (1)
Effect of Stem Cell Source From Unrelated Donors on Transplant Outcomes In Severe Aplastic Anemia (SAA): a Comparison of Unrelated Bone Marrow (BM) and Peripheral Blood Progenitor Cells (PBPC) (2010) (1)
Jumping Translocations in Myelodysplastic Syndromes (2016) (1)
Co-Transplantation of Stromal Cells Enhances Engraftment Ability of MDS-Derived Hematopoietic Precursors in NOD/SCID-b2microglobulin-Deficient (b2mnull) Mice. (2005) (1)
Collection, Processing and Infusion of Marrow (1992) (1)
Long-term survival of dogs given unrelated DLA nonidentical marrow grafts and cyclosporin A (CyA) and methotrexate (MTX) - Tolerance mediated by nylon-wool adherent suppressor cells? (1981) (1)
More than one angle to target aplastic anemia? (2018) (1)
Absence of major histocompatibility class II expression does not impair hematopoiesis in mice. (2001) (1)
Cytoprotective effect of transferrin (Tf) in stress-induced apoptosis (1998) (1)
Number of Courses of Induction Therapy Independently Predicts Outcome after Allogeneic Transplantation for AML in First Morphological Remission (2015) (1)
Introduction to Hematopoietic Cell Transplantation (2016) (1)
Deciding on transplantation for myelofibrosis (2004) (1)
Long-term survival with mixed chimerism in patients with AML and MDS transplanted after conditioning with targeted busulfan, fludarabine, and thymoglobulin (2021) (1)
Chimeras - no longer a myth. (1983) (1)
Preparation for Marrow Transplantation (1988) (1)
Stem cell transplantation for myelodysplasia. (2001) (0)
Abnormalities of the αβ T cell receptor repertoire in advanced myelodysplastic syndrome (2010) (0)
The Jumanjii Histone Demethylase KDM2B controls EZH2 Expression In Myelodysplastic Syndromes (MDS) Via Mir Let-7b (let7b), a Pathway That Is Bypassed By The Histone Methylation Inhibitor DZNep (2013) (0)
Allogeneic Hematopoietic Cell Transplantation Is Effective In Patients With Advanced Systemic Mastocytosis: A Multicenter Retrospective Analysis (2013) (0)
The Role of TWIST1 Gene Expression and Hypoxic Microenvironment in Acute Myeloid Leukemia (2015) (0)
Phase II Trial of Eprenetapopt (APR-246) in Combination with Azacitidine (AZA) As Maintenance Therapy for TP53 mutated Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS) Following Allogeneic Hematopoietic Cell Transplantation (HCT) (2022) (0)
Long-Term Adjustments (1988) (0)
Intrathymic maturation of CD4+ T-lymphocytes in an MHC class II deficient transplant model. (1997) (0)
Chronic Graft versus Host Disease: Interdisciplinary Management: Secondary Malignancies and Other Late Effects (2009) (0)
Unique immunologic problems in human bone marrow transplant recipients. (1981) (0)
Myeloid Dyspoiesis as Determined by Flow Cytometry Is a More Powerful Predictor of Post-Transplant Relapse with MDS Than the Marrow Myeloblast Count. (2007) (0)
Abstract #5182: Genome wide assessment of epigenetic alterations in Ewing Sarcoma (2009) (0)
Somatic Expansion of the Frataxin Gene GAA Repeats in MDS Patients. (2008) (0)
NF- κ B and FLIP in Arsenic Trioxide (ATO)-Induced Apoptosis in Myelodysplastic Syndromes (MDS) (2005) (0)
Abstract 6183: PARP inhibitors preferentially sensitize splicing factor mutant myeloid neoplasms (2023) (0)
Identification of DJ-1/Park-7 as a Determinant of Tnfα-Induced and Stroma-Dependent Apoptosis in Leukemia Using Mass Spectometry and Phosphopetide Analysis. (2008) (0)
Evaluation of the impact of antithymocyte globuline on lung function at 1 year after allogeneic stem cell transplantation (2011) (0)
Myelodysplastic Syndrome (2005) (0)
Cost and Availability of Transplantation (1992) (0)
42 Reducing the frequency of relapse after hematopoietic cell transplantation for MDS (2009) (0)
Genetics, prognosis, and transplantation for myelofibrosis (2018) (0)
A Randomized Phase II Study of Tosedostat in Combination with Either Cytarabine or Decitabine in Newly Diagnosed Older Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome (2014) (0)
A Retrospective Comparison of Tacrolimus Vs. Cyclosporine for Immunosuppression After Allogeneic Hematopoietic Cell Transplantation with G-CSF-Mobilized Blood Cells (2010) (0)
Secondary Leukemia or Myelodysplasia Treated by Bone Marrow Transplantation (2001) (0)
Treatment Planning and Timing of Transplantation (1992) (0)
Management of the Critically Ill Marrow Transplant Patient (1988) (0)
Erythema multiforme-like skin eruptions localized to marrow aspiration sites after autologous marrow transplantation. (1985) (0)
Myelodysplastic syndromes, second edition (2013) (0)
Transplantation-Specific Cytogenetics Grouping Scheme for Patients with Myelodysplastic Syndromes: A Multicenter Validation Study (2008) (0)
Cyclosporine in marrow transplantation (1983) (0)
Differential Effects of Bexarotene on Intrinsic and Extrinsic Pathways in TRAIL-Induced Apoptosis in Myeloid Leukemia Cell Lines. (2006) (0)
Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome: Current Status (2011) (0)
Germline-Somatic Interactions in Myelofibrosis Susceptibility (2021) (0)
Acute Graft-Versus-Host Disease (GVHD) (1992) (0)
Association between Prior Cytotoxic Therapy, Antecedent Hematologic Disorder, and Outcome after Allogeneic Hematopoietic Cell Transplantation in Adult Acute Myeloid Leukemia (2023) (0)
Utility of Targeted Gene Sequencing to Differentiate Myeloid Malignancies from other Cytopenic Conditions. (2023) (0)
A Randomized Phase II Study of Tosedostat in Combination with Either Cytarabine or Decitabine in Newly Diagnosed Older Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome (2014) (0)
Abstract 1503: Myelodysplasia bone marrow stromal cells have widespread aberrant hypermethylation that is targeted by treatment with DNMT inhibitors. (2013) (0)
A Novel Somatic Mutation in IKZF1 Is Common in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant for Myelofibrosis (2016) (0)
Optimized Cyclophosphamide (CY) Dosing in Combination with Fludarabine, TBI and ATG As Conditioning for Unrelated Donor Bone Marrow Transplantation (BMT) in Severe Aplastic Anemia (SAA): A Phase I/II Study from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) (2014) (0)
Neuroendocrine Function, Growth and Development (1992) (0)
Nonmalignant hematalogical disorders (1995) (0)
59-year-old man with MDS. (2009) (0)
Homing and Immunogenicity of Murine Stromal Cells Transfected with Xenogeneic Mhc Class II Genes (1995) (0)
Induction ofHepatic Veno-occiusive Disease in Dogs (2007) (0)
DOCUMENTATION OF ALLOGENEIC MARROW ENGRAFTMENT BY DNA ANALYSIS OF URINARY LEUCOCYTES (1991) (0)
outcome after hemopoietic stem cell transplantation scoring in myelodysplastic syndromes correlates with the IPSS and with Myeloid and monocytic dyspoiesis as determined by flow cytometric (2013) (0)
Abstract IA36:SRSF2mutations impair hematopoietic differentiation by altering exonic splicing enhancer preference. (2015) (0)
Transplantation For Myelodysplastic Syndrome Evolving From Aplastic Anemia Treated With Immunosuppressive Therapy: From The Fred Hutchinson Cancer Research Center and Center For International Bone Marrow Transplantation Research (2013) (0)
Whole-genome sequencing identifies novel predictors for hematopoietic cell transplant outcomes for patients with myelodysplastic syndrome: a CIBMTR study (2023) (0)
Evolutions in the Clinical Management of GVHD (2019) (0)
A Novel Shuttle Vector Approach to Identify Genes Involved in Hematopoietic Stem Cell Disorders using Vector-mediated Genotoxicity. (2014) (0)
Myelodysplastic syndromes: from neglect to prominence. (2010) (0)
Choosing a Regimen for Prophylaxis of Graft-versus-Host Disease (2012) (0)
Bone marrow and hemopoietic stem cell transplantation (2007) (0)
Topic: AS08-Treatment/AS08a-Current treatment options - Hypomethylating agents (2021) (0)
Central Nervous System (1992) (0)
Resistance to allogeneic marrow grafts in dogs (1981) (0)
Kidneys and Urinary Tract (1992) (0)
A Phase II Trial Combining Radiolabeled Anti-CD45 Antibody with Fludarabine and Low-Dose Total Body Irradiation (TBI) Followed by Related or Unrelated Hematopoietic Cell Transplantation for Patients Under Age 50 with Advanced Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS) (2012) (0)
Health-Related Quality of Life and Vulnerability among People with Myelodysplastic Syndromes: A US National Study. (2023) (0)
α1 Anti-Trypsin (AAT) Mitigates Hematopoietic Injury and Enhances Bone Marrow Recovery After Total Body Irradiation (TBI) (2012) (0)
Myeloablative Umbilical Cord Blood Transplantation for Hematologic Malignancies Is Comparable to Unrelated Donor Transplantation: A Retrospective Single-Center Study (2012) (0)
When and how to transplant patients with myelofibrosis (2015) (0)
278: Treosulfan Plus Fludarabine for Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients with Acute Leukemia and Myelodysplastic Syndrome (2008) (0)
Safety and Efficacy of Fedratinib in Patients with Primary (P), Post-Polycythemia Vera (Post-PV), and Post-Essential Thrombocythemia (Post-ET) Myelofibrosis (MF) Previously Treated with Ruxolitinib: Primary Analysis of the FREEDOM Trial (2022) (0)
Cyclosporin A (CyA) in marrow transplantation in dogs (1980) (0)
TRANSPLANTATION a-1-Antitrypsin ( AAT ) – modi fi ed donor cells suppress GVHD but enhance the GVL effect : a role for mitochondrial bioenergetics (2014) (0)
Allogeneic hematopoietic cell transplantation in patients 60 to 70 years of age with de novo high-risk MDS or secondary AML – a comparison with patients lacking donors who received azacitidine Biol Blood Marrow Transplant (2015) (0)
New M alignant D iseases A fter A llogeneic M arrow Transplantation f or C hildhood A cute L eukemia (2000) (0)
Hematopoietic Cell Transplantation (HCT) (2013) (0)
Antithymocyte Globuline Given as Part of the Conditioning Regimen Has No Impact On Lung Function at 1 Year After Transplantation. (2009) (0)
The Presence of HLA DR15 Antigen in Patients with Severe Aplastic Anemia Does Not Impact Engraftment and Survival After HLA-Identical Sibling Transplantation. (2009) (0)
Individuals, Boundaries and GVHD. (2020) (0)
Prognostic landscape of mitochondrial genome in myelodysplastic syndrome after stem-cell transplantation (2023) (0)
The message is not the median! Author's reply (2004) (0)
Late Relapse After Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome (2012) (0)
Allogeneic hematopoietic stem cell transplantation for myeloﬁbrosis (2003) (0)
Frequency Of Allogeneic Stem Cell Transplant (SCT) In Patients Presenting With Newly-Diagnosed AML Or AML At Time Of First Salvage Therapy (2010) (0)
Hematopoietic Cell Transplantation for Myelodysplastic Syndromes and Myeloproliferative Neoplasms (2016) (0)
JAK2 V617F Mutation and Associated Chromosomal Alterations Involving JAK2 in Pre-HCT Blood Samples and Transplant Outcomes in Myelofibrosis Subtypes (2022) (0)
MODULAATE, A 2-Part, Dose-Finding, Efficacy and Safety Trial with Alpha-1 Antitrypsin (AAT) for Prevention of Acute Graft vs. Host Disease (aGVHD): Part 1 Safety and Pharmacokinetic (PK) Results (2022) (0)
Modulated Cyclophosphamide-Based In Vivo T-Cell Depletion Promotes Engraftment With Minimal Gvhd and Low Toxicity In Fanconi Anemia Patients (2013) (0)
Analysis of the αβ T Cell Receptor Repertoire in Advanced Myelodysplastic Syndrome (2008) (0)
Topic: AS08-Treatment/AS08f-Clinical trials – Phase II-III: EFFICACY AND SAFETY OF ORAL DECITABINE/CEDAZURIDINE (ASTX727) IN THE CMML SUBPOPULATION FROM PHASE 2 AND ASCERTAIN PHASE 3 STUDIES (2023) (0)
Fludarabine-Based Conditioning for Allogeneic Marrow Transplantation From Unrelated Donors in Severe Aplastic Anemia (SAA): Serious and Unexpected Adverse Events in Pre-Defined Cyclophosphamide (CY) Dose Levels (2011) (0)
Asymmetric dimethylarginine – a prognostic marker for transplant outcome? (2019) (0)
Bone marrow toxicity of total-body irradiation combined with radiosensitizers. (1989) (0)
Results of Allogeneic Hematopoietic Cell Transplantation in Persons with Fanconi Anemia and Pretransplant Cytogenetic Abnormalities, Myelodysplastic Syndrome, or Acute Leukemia (2011) (0)
Follow-Up after Discharge from the Transplant Center (1992) (0)
Inducible Levels of Gelatinase B/Matrix Metalloproteinase-9 Gene Expression in Monocytes Are Associated with Marrow Cellularity in Myelodysplastic Syndrome (MDS). (2005) (0)
Interleukin-32, α1 Anti-Trypsin (AAT-1) and Graft-Versus-Host-Disease (2010) (0)
Alpha 1 Anti-Trypsin (AAT) Offers Potent Therapy for Steroid Resistant Gut Gvhd: Interim Results of a Phase I/II Clinical Study (2014) (0)
transplantation high- dose busulfan or total-body irradiation and bone marrow Pregnancies following high-dose cyclophosphamide with or without (2011) (0)
Graft-vs.-Host Disease as a Th1-Type Process: Regulation by Th2-Type Cells (2004) (0)
Other Delayed Complications (1992) (0)
FLIP Long(L) and FLIP Short(S) Overexpression in the Human Myeloid Leukemia Cell Line ML-1 and Its Role in TRAIL [Tumor Necrosis Factor(TNF)-Related Apoptosis-Inducing Ligand] and TNFa Induced Apoptosis. (2005) (0)
Regulatory Reprogramming of Erythropoiesis By DNMT3A Mutation (2018) (0)
Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndrome: Effect of Transplant Conditioning Regimen Intensity on Outcomes (2017) (0)
marrow with anti-Ia monoclonal antibody Failure of autologous marrow reconstitution after cytolytic treatment of (2011) (0)
Marrow Graft Failure (1992) (0)
Silver Lining: Reduced Relapse with Chronic GVHD after Transplant for MDS (2020) (0)
Transferrin (Tf) Mediated Protection of the Liver Against Fas-Induced Injury Requires Tf-Receptor Type 2 and Is Modulated by Baseline Plasma Iron Levels. (2006) (0)
I-016 GVHD and GVL effects in patients with MDS (2013) (0)
DLA-nonidentical unrelated marrow grafts after high-dose total body irradiation: granulocyte colony-stimulating factor treatment after transplant does not enhance engraftment. (1996) (0)
Frequency of Allogeneic Stem Cell Transplant(SCT) in Patients Presenting with Newly-Diagnosed AML or AML at Time of First Salvage Therapy. (2009) (0)
O-57 Hemopoietic cell transplantationfor the treatment of MDS* (2005) (0)
Canine bronchoalveolar cells: Antigen-presenting macrophages are Ia-positive, lymphocytes are of non-B lineage (1983) (0)
Immunosuppression After Marrow Transplant CTLA4Ig, and 100 cGy Total Body Irradiation Before and Pharmacologic Stable Mixed Hematopoietic Chimerism in Dogs Given Donor Antigen, (2013) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With H. Joachim J. Deeg?

H. Joachim J. Deeg is affiliated with the following schools:

H. Joachim J. Deeg's Academic­Influence.com Rankings

H. Joachim J. Deeg's Degrees

Why Is H. Joachim J. Deeg Influential?

H. Joachim J. Deeg's Published Works

Published Works

What Schools Are Affiliated With H. Joachim J. Deeg?

H. Joachim J. Deeg's AcademicInfluence.com Rankings